
This month, Novo Nordisk has initiated a phase II trial with the firm's cholesterol-lowering PCSK9i inhibitor, according to the Danish pharmaceutical firm's Q2 report, published on Wednesday afternoon.
In contrast to the phase I trial, Novo Nordisk will now be testing the peptide-based drug as an oral solution using the same technology that the pharmaceutical company is using for its popular diabetes candidate Rybelsus.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app